[go: up one dir, main page]

FI20075278A0 - Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet - Google Patents

Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet

Info

Publication number
FI20075278A0
FI20075278A0 FI20075278A FI20075278A FI20075278A0 FI 20075278 A0 FI20075278 A0 FI 20075278A0 FI 20075278 A FI20075278 A FI 20075278A FI 20075278 A FI20075278 A FI 20075278A FI 20075278 A0 FI20075278 A0 FI 20075278A0
Authority
FI
Finland
Prior art keywords
vap
monoclonal antibodies
human anti
completely human
novel completely
Prior art date
Application number
FI20075278A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
David John Smith
Petri Vainio
Jari Mikkola
Paeivi Vuorio
Jani Vainio
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Priority to FI20075278A priority Critical patent/FI20075278A0/fi
Publication of FI20075278A0 publication Critical patent/FI20075278A0/fi
Priority to EP13190488.0A priority patent/EP2692737B1/fr
Priority to PL13190488T priority patent/PL2692737T3/pl
Priority to AU2008240560A priority patent/AU2008240560B2/en
Priority to RS20150427A priority patent/RS54066B1/en
Priority to CA2683079A priority patent/CA2683079C/fr
Priority to DK08736848.6T priority patent/DK2164872T3/en
Priority to JP2010503537A priority patent/JP5728225B2/ja
Priority to PT13190488T priority patent/PT2692737T/pt
Priority to CA2962519A priority patent/CA2962519C/fr
Priority to PCT/FI2008/050199 priority patent/WO2008129124A1/fr
Priority to LTEP13190488.0T priority patent/LT2692737T/lt
Priority to SI200831444T priority patent/SI2164872T1/sl
Priority to EP08736848.6A priority patent/EP2164872B1/fr
Priority to UAA200910613A priority patent/UA97516C2/ru
Priority to DK13190488.0T priority patent/DK2692737T3/en
Priority to KR1020097021869A priority patent/KR101352416B1/ko
Priority to NZ580194A priority patent/NZ580194A/en
Priority to ES08736848.6T priority patent/ES2540566T3/es
Priority to ES13190488.0T priority patent/ES2690307T3/es
Priority to CA3059571A priority patent/CA3059571C/fr
Priority to SI200832000T priority patent/SI2692737T1/sl
Priority to RU2009142808/10A priority patent/RU2459832C2/ru
Priority to HUE13190488A priority patent/HUE041656T2/hu
Priority to CA3059580A priority patent/CA3059580C/fr
Priority to CA3059600A priority patent/CA3059600C/fr
Priority to CN2008800209043A priority patent/CN101679523B/zh
Priority to PL08736848T priority patent/PL2164872T3/pl
Priority to PT87368486T priority patent/PT2164872E/pt
Priority to US12/081,707 priority patent/US7897149B2/en
Priority to ZA200907220A priority patent/ZA200907220B/xx
Priority to IL201601A priority patent/IL201601A/en
Priority to HK10107584.5A priority patent/HK1141039A1/xx
Priority to US12/940,476 priority patent/US8142783B2/en
Priority to HRP20150615TT priority patent/HRP20150615T1/hr
Priority to CY20151100533T priority patent/CY1116413T1/el
Priority to HRP20181616TT priority patent/HRP20181616T1/hr
Priority to CY181101032T priority patent/CY1121132T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
FI20075278A 2007-04-20 2007-04-20 Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet FI20075278A0 (fi)

Priority Applications (38)

Application Number Priority Date Filing Date Title
FI20075278A FI20075278A0 (fi) 2007-04-20 2007-04-20 Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
PT87368486T PT2164872E (pt) 2007-04-20 2008-04-17 Anticorpos monoclonais anti-vap-1 totalmente humanos
ES08736848.6T ES2540566T3 (es) 2007-04-20 2008-04-17 Anticuerpos monoclonales anti-VAP-1 completamente humanos
ES13190488.0T ES2690307T3 (es) 2007-04-20 2008-04-17 Anticuerpos monoclonales anti-VAP-1 completamente humanos
AU2008240560A AU2008240560B2 (en) 2007-04-20 2008-04-17 Novel fully human anti-VAP-1 monoclonal antibodies
RS20150427A RS54066B1 (en) 2007-04-20 2008-04-17 COMPLETELY HUMAN ANTI-VAP-1 MONOCLONAL ANTIBODIES
CA2683079A CA2683079C (fr) 2007-04-20 2008-04-17 Nouveaux anticorps monoclonaux anti-vap-1 entierement humains
SI200832000T SI2692737T1 (sl) 2007-04-20 2008-04-17 V celoti humana proti -VAP-1 monoklonalna protitelesa
JP2010503537A JP5728225B2 (ja) 2007-04-20 2008-04-17 完全ヒト抗ｖａｐ−１抗体、ｖａｐ−１結合断片、核酸分子、発現ベクター、宿主細胞、及び、薬学的組成物
PT13190488T PT2692737T (pt) 2007-04-20 2008-04-17 Anticorpos monoclonais anti-vap-1 totalmente humanos
CA2962519A CA2962519C (fr) 2007-04-20 2008-04-17 Nouveaux anticorps monoclonaux anti-vap-1 entierement humains
PCT/FI2008/050199 WO2008129124A1 (fr) 2007-04-20 2008-04-17 Nouveaux anticorps monoclonaux anti-vap-1 entièrement humains
LTEP13190488.0T LT2692737T (lt) 2007-04-20 2008-04-17 Pilnai žmogaus anti-vap-1 monokloniniai antikūnai
SI200831444T SI2164872T1 (sl) 2007-04-20 2008-04-17 V celoti humana proti -VAP-1 monoklonalna protitelesa
EP08736848.6A EP2164872B1 (fr) 2007-04-20 2008-04-17 Anticorps monoclonaux anti-vap-1 entièrement humains
UAA200910613A UA97516C2 (ru) 2007-04-20 2008-04-17 Полностью человеческое моноклональное антитело против vap-1
DK13190488.0T DK2692737T3 (en) 2007-04-20 2008-04-17 Fully human anti-VAP-1 monoclonal antibodies
KR1020097021869A KR101352416B1 (ko) 2007-04-20 2008-04-17 신규의 완전한 사람형 항-ｖａｐ-1 모노클로날 항체
NZ580194A NZ580194A (en) 2007-04-20 2008-04-17 Novel fully human anti-vap-1 monoclonal antibodies
EP13190488.0A EP2692737B1 (fr) 2007-04-20 2008-04-17 Anticorps monoclonaux anti-VAP-1 entièrement humains
CA3059571A CA3059571C (fr) 2007-04-20 2008-04-17 Nouveaux anticorps monoclonaux anti-vap-1 entierement humains
PL13190488T PL2692737T3 (pl) 2007-04-20 2008-04-17 W pełni ludzkie przeciwciała monoklonalne anty-vap-1
DK08736848.6T DK2164872T3 (en) 2007-04-20 2008-04-17 COMPLETE human anti-VAP-1 MONOCLONAL ANTIBODIES
RU2009142808/10A RU2459832C2 (ru) 2007-04-20 2008-04-17 Новые полностью человеческие моноклональные антитела против vap-1
HUE13190488A HUE041656T2 (hu) 2007-04-20 2008-04-17 Teljesen humán anti-VAP-1 monoklonális antitestek
CA3059580A CA3059580C (fr) 2007-04-20 2008-04-17 Nouveaux anticorps monoclonaux anti-vap-1 entierement humains
CA3059600A CA3059600C (fr) 2007-04-20 2008-04-17 Nouveaux anticorps monoclonaux anti-vap-1 entierement humains
CN2008800209043A CN101679523B (zh) 2007-04-20 2008-04-17 全人源抗vap-1单克隆抗体
PL08736848T PL2164872T3 (pl) 2007-04-20 2008-04-17 W pełni ludzkie przeciwciała monoklonalne anty-vap-1
US12/081,707 US7897149B2 (en) 2007-04-20 2008-04-18 Fully human anti-VAP-1 monoclonal antibodies
ZA200907220A ZA200907220B (en) 2007-04-20 2009-10-15 Novel fully human anti-VAP-1 monoclonal antibodies
IL201601A IL201601A (en) 2007-04-20 2009-10-18 Human monoclonal antibodies to vap-1
HK10107584.5A HK1141039A1 (en) 2007-04-20 2010-08-09 Fully human anti-vap-1 monoclonal antibodies vap-1
US12/940,476 US8142783B2 (en) 2007-04-20 2010-11-05 Methods of treating an inflammatory condition involving VAP-1-mediated adhesion with VAP-1-specific antibodies
HRP20150615TT HRP20150615T1 (hr) 2007-04-20 2015-06-08 Potpuno ljudska anti-vap-1 monoklonska protutijela
CY20151100533T CY1116413T1 (el) 2007-04-20 2015-06-23 Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
HRP20181616TT HRP20181616T1 (hr) 2007-04-20 2018-10-05 Potpuno ljudska anti-vap-1 monoklonska antitijela
CY181101032T CY1121132T1 (el) 2007-04-20 2018-10-05 ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20075278A FI20075278A0 (fi) 2007-04-20 2007-04-20 Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet

Publications (1)

Publication Number Publication Date
FI20075278A0 true FI20075278A0 (fi) 2007-04-20

Family

ID=38009931

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20075278A FI20075278A0 (fi) 2007-04-20 2007-04-20 Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet

Country Status (25)

Country Link
US (2) US7897149B2 (fr)
EP (2) EP2164872B1 (fr)
JP (1) JP5728225B2 (fr)
KR (1) KR101352416B1 (fr)
CN (1) CN101679523B (fr)
AU (1) AU2008240560B2 (fr)
CA (5) CA3059571C (fr)
CY (2) CY1116413T1 (fr)
DK (2) DK2692737T3 (fr)
ES (2) ES2690307T3 (fr)
FI (1) FI20075278A0 (fr)
HK (1) HK1141039A1 (fr)
HR (2) HRP20150615T1 (fr)
HU (1) HUE041656T2 (fr)
IL (1) IL201601A (fr)
LT (1) LT2692737T (fr)
NZ (1) NZ580194A (fr)
PL (2) PL2164872T3 (fr)
PT (2) PT2164872E (fr)
RS (1) RS54066B1 (fr)
RU (1) RU2459832C2 (fr)
SI (2) SI2692737T1 (fr)
UA (1) UA97516C2 (fr)
WO (1) WO2008129124A1 (fr)
ZA (1) ZA200907220B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20075278A0 (fi) * 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
EP2427493A1 (fr) 2009-05-08 2012-03-14 F. Hoffmann-La Roche AG Anticorps anti-egfl1 humanisés, et procédés d'utilisation correspondants
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
TWI594764B (zh) * 2010-04-12 2017-08-11 生化治療公司 治療用途
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
ES2702246T3 (es) * 2012-03-26 2019-02-28 Sanofi Sa Formulaciones de agente de unión IgG4 estables
EP3387898B1 (fr) * 2013-03-15 2020-05-13 Mayo Foundation for Medical Education and Research Identification et surveillance d'immunoglobulines monoclonales par la masse moléculaire
CA2915163A1 (fr) 2013-06-12 2014-12-18 Proximagen Limited Nouvelles utilisations therapeutiques d'inhibiteurs enzymatiques
CA2944767C (fr) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotypage d'immunoglobulines par masse moleculaire precise
WO2015189534A1 (fr) 2014-06-12 2015-12-17 Proximagen Limited Inhibiteurs de vap-1 pour le traitement de la dystrophie musculaire
EP3175242A4 (fr) 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantification d'agents thérapeutiques de type anticorps monoclonaux par lc-ms/ms
CN104628853B (zh) * 2015-02-06 2017-10-10 中国人民解放军南京军区军事医学研究所 人源抗炭疽保护性抗原PA的抗体IgG及其应用
AU2016326757B2 (en) 2015-09-24 2022-09-01 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
CA3007768A1 (fr) 2015-12-07 2017-06-15 Benevolentai Cambridge Limited Inhibiteurs de vap-1 pour le traitement de la douleur
WO2017194499A1 (fr) * 2016-05-09 2017-11-16 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Exosomes spécifiques du tissu comme biomarqueurs
CN109863395B (zh) 2016-09-07 2023-05-23 梅约医学教育与研究基金会 分子量法鉴定和监测裂解免疫球蛋白
US11427634B2 (en) 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
EP3681528A4 (fr) 2017-09-13 2021-07-21 Mayo Foundation for Medical Education and Research Identification et surveillance d'un inhibiteur d'apoptose de macrophage
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
CN111537740B (zh) * 2020-05-22 2021-11-23 长春生物制品研究所有限责任公司 一种森林脑炎病毒IgM抗体检测试剂盒及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
HU217175B (hu) * 1992-06-09 1999-12-28 Oy Biotie Therapies Ltd. Új belhámvaszkuláris protein-1 (VAP-1), amely emberben a limfociták kötődését mediálja
US5580780A (en) * 1992-06-09 1996-12-03 Jalkanen; Sirpa Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
CA2161351C (fr) 1993-04-26 2010-12-21 Nils Lonberg Animaux transgeniques, pouvant produire des anticorps heterologues
WO1998053049A1 (fr) * 1997-05-23 1998-11-26 Biotie Therapies Ltd. Proteine-1 d'adhesion vasculaire a activite monoamine-oxydase
WO2003084469A2 (fr) * 2002-04-01 2003-10-16 Utah Ventures Ii, L.P. Proteines de membranes endotheliales specifiques de tissus
ATE354655T1 (de) 1999-08-24 2007-03-15 Medarex Inc Humane antikörper gegen ctla-4 und deren verwendungen
FI20020807A0 (fi) 2002-04-29 2002-04-29 Biotie Therapies Oyj Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
FI20075278A0 (fi) * 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet

Also Published As

Publication number Publication date
CA3059600C (fr) 2020-06-30
HUE041656T2 (hu) 2019-05-28
UA97516C2 (ru) 2012-02-27
EP2164872A4 (fr) 2011-01-12
JP2010524449A (ja) 2010-07-22
RS54066B1 (en) 2015-10-30
SI2692737T1 (sl) 2019-04-30
JP5728225B2 (ja) 2015-06-03
SI2164872T1 (sl) 2015-07-31
US7897149B2 (en) 2011-03-01
LT2692737T (lt) 2018-10-25
US20110117021A1 (en) 2011-05-19
WO2008129124A1 (fr) 2008-10-30
CY1121132T1 (el) 2019-12-11
CN101679523B (zh) 2013-11-06
CA2683079C (fr) 2017-04-11
PT2164872E (pt) 2015-07-30
RU2009142808A (ru) 2011-05-27
CA2962519A1 (fr) 2008-10-30
CA2683079A1 (fr) 2008-10-30
CA3059571C (fr) 2020-06-30
EP2164872B1 (fr) 2015-05-27
US20090081126A1 (en) 2009-03-26
CY1116413T1 (el) 2017-02-08
US8142783B2 (en) 2012-03-27
KR20100021562A (ko) 2010-02-25
PL2692737T3 (pl) 2019-07-31
IL201601A (en) 2015-06-30
PL2164872T3 (pl) 2015-08-31
HK1141039A1 (en) 2010-10-29
HRP20150615T1 (hr) 2015-07-03
KR101352416B1 (ko) 2014-01-17
NZ580194A (en) 2011-09-30
EP2692737B1 (fr) 2018-07-25
CA3059580A1 (fr) 2008-10-30
RU2459832C2 (ru) 2012-08-27
HRP20181616T1 (hr) 2018-12-14
ZA200907220B (en) 2010-07-28
CA3059600A1 (fr) 2008-10-30
PT2692737T (pt) 2018-10-25
EP2164872A1 (fr) 2010-03-24
CN101679523A (zh) 2010-03-24
AU2008240560A1 (en) 2008-10-30
DK2692737T3 (en) 2018-10-29
ES2540566T3 (es) 2015-07-10
ES2690307T3 (es) 2018-11-20
IL201601A0 (en) 2010-05-31
CA2962519C (fr) 2019-12-31
EP2692737A1 (fr) 2014-02-05
CA3059580C (fr) 2020-06-30
CA3059571A1 (fr) 2008-10-30
AU2008240560B2 (en) 2012-05-17
DK2164872T3 (en) 2015-06-29

Similar Documents

Publication Publication Date Title
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
LTPA2018017I1 (lt) Žmogaus CGRP receptorių rišantys antikūnai
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0809677A2 (pt) Anticorpos anti-ige
DK2066695T3 (da) Anti-myostatin-antistoffer
NO344963B1 (no) Humanisert antistoff
SMT201700083B (it) Anticorpi monoclonali
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
BRPI0819165A2 (pt) Anticorpos anti-vegf
EP2207803A4 (fr) Anticorps humains spécifiques de cd9
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0817273A2 (pt) Região constante de anticorpo modificada
EP2211903A4 (fr) Anticorps anti-cll-1
BRPI0907237A2 (pt) Anticorpo anti-cldn6
EP2324359A4 (fr) Anticorps monoclonal stro-4
EP2337798A4 (fr) Anticorps spécifiques de l'asb
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
EP2172483A4 (fr) ANTICORPS ANTI-Muc17
BRPI0817427A2 (pt) Anticorpo anti-bst2